
2019年以来のOpenAI最高経営責任者であるサム・アルトマンがメトホルミンを服用しているという信頼できる証拠は存在しない。
この主張は公開記録、健康開示、または検証済みの報道に根拠がない。
アルトマンの健康情報は非公開のままである。
Altman's documented activities center on OpenAI's product roadmap. Recent initiatives include OpenAI Dots, his unveiled ChatGPT AI personal agent, alongside the 2026 DevDay announcements. His tracked signals show 94 connections to Artificial Intelligence developments.
Health rumors about prominent figures often circulate online without verification. Without direct statements from Altman or credible medical sources, claims about his medications should be treated as unsubstantiated speculation rather than fact.